Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097530 - IMMUNOTHERAPY TARGETING MESOTHELIN

Publication Number WO/2020/097530
Publication Date 14.05.2020
International Application No. PCT/US2019/060570
International Filing Date 08.11.2019
IPC
C07K 14/725 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
Applicants
  • FRED HUTCHINSON CANCER RESEARCH CENTER [US]/[US]
  • JUNO THERAPEUTICS, INC. [US]/[US]
Inventors
  • SCHMITT, Thomas M.
  • CHAPUIS, Aude G.
  • GREENBERG, Philip D.
Agents
  • EIDT, Chandra, E.
  • OBEIDAT, Baha, A.
  • KUMABE, Blake, K.
  • SOLTANI, Bobby, B.
  • ZENTZ, Bradley, J.
  • SARGEANT, Brooke
  • QUIST, Brooke, W.
  • ROTH, Carol, J.
  • WITTKOPP, Cristina, J.
  • O'BRIEN, Daniel
  • CARLSON, David, V.
  • STARK, Duncan
  • TARLETON, E., Russell
  • SUN, Eileen, S.
  • HARWOOD, Eric, A.
  • GERTZ, Glenda, A.
  • HAN, Hai
  • TALBERT, Hayley, J.
  • BARRETT, Jared, M.
  • MIXCO, Javier, M.
  • SAKOI, Jeffrey, M.
  • BAUNACH, Jeremiah, J.
  • ZHANG, Jianping
  • MORGAN, John, A.
  • WAKELEY, John, J.
  • COE, Justin, E.
  • HENCKEL, Karen, M.
  • HEFTER, Karl, A.
  • HERMANNS, Karl, R.
  • CLAYTON, Kenneth, W.
  • MORGAN, Kevan, L.
  • COSTANZA, Kevin, S.
  • COOPER, Michael, P.
  • RUSYN, Paul
  • LIN, Qing
  • HALLER, Rachel, A.
  • IANNUCCI, Robert
  • WEBB, Samuel, E.
  • LIU, Shi
  • LEEK, Shoko, I.
  • ROSENMAN, Stephen, J.
  • LAWRENZ, Steven, D.
  • ABEDI, Syed
  • BOLLER, Timothy, L.
  • LIGON, Toby, J.
  • SHEWMAKE, Thomas, A.
  • CANTRELL, Tyler, C.
  • SAKOI, Zachary, M.
Priority Data
62/758,39709.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOTHERAPY TARGETING MESOTHELIN
(FR) IMMUNOTHÉRAPIE CIBLANT LA MÉSOTHÉLINE
Abstract
(EN)
Binding proteins specific for Msln20-28 or Msln530-538 peptides are provided herein. Polynucleotides encoding the binding proteins, as well as compositions and recombinant host cells comprising the binding proteins or polynucleotides are also provided. The compositions and recombinant host cells may be used to treat a subject having mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, a cancer wherein an Msln20-28 peptide is expressed on a tumor cell of the cancer, or a cancer wherein an Msln530-538 peptide is expressed on a tumor cell of the cancer.
(FR)
La présente invention concerne des protéines de liaison spécifiques des peptides Msln20-28 ou Msln530-538. L'invention concerne également des polynucléotides codant pour les protéines de liaison, ainsi que des compositions et des cellules hôtes recombinantes comprenant les protéines de liaison ou les polynucléotides. Les compositions et les cellules hôtes recombinantes peuvent être utilisées pour traiter un sujet souffrant d'un mésothéliome, d'un cancer du pancréas, d'un cancer de l'ovaire, d'un cancer du poumon, d'un cancer dans lequel un peptide Msln20-28 est exprimé sur une cellule tumorale du cancer, ou d'un cancer dans lequel un peptide Msln530-538 est exprimé sur une cellule tumorale du cancer.
Latest bibliographic data on file with the International Bureau